BIOGEN INC (IDP.DE) Stock Fundamental Analysis
Europe - FRA:IDP - US09062X1037 - Common Stock
144.1 EUR
+1.15 (+0.8%)
Taking everything into account, IDP scores 5 out of 10 in our fundamental rating. IDP was compared to 75 industry peers in the Biotechnology industry. IDP is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. IDP is cheap, but on the other hand it scores bad on growth. With these ratings, IDP could be worth investigating further for value investing!.
1. Profitability
1.1 Basic Checks
IDP had positive earnings in the past year.
In the past year IDP had a positive cash flow from operations.
Each year in the past 5 years IDP has been profitable.
In the past 5 years IDP always reported a positive cash flow from operatings.
1.2 Ratios
IDP's Return On Assets of 5.51% is fine compared to the rest of the industry. IDP outperforms 80.00% of its industry peers.
The Return On Equity of IDP (8.84%) is better than 81.33% of its industry peers.
The Return On Invested Capital of IDP (9.70%) is better than 86.67% of its industry peers.
The Average Return On Invested Capital over the past 3 years for IDP is below the industry average of 12.96%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROIC | 9.7% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.4%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
Looking at the Profit Margin, with a value of 15.99%, IDP belongs to the top of the industry, outperforming 82.67% of the companies in the same industry.
IDP's Profit Margin has declined in the last couple of years.
IDP's Operating Margin of 28.50% is amongst the best of the industry. IDP outperforms 85.33% of its industry peers.
IDP's Operating Margin has declined in the last couple of years.
IDP has a better Gross Margin (75.24%) than 69.33% of its industry peers.
IDP's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.99% | ||
| GM | 75.24% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.98%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so IDP is still creating some value.
IDP has more shares outstanding than it did 1 year ago.
The number of shares outstanding for IDP has been reduced compared to 5 years ago.
IDP has a better debt/assets ratio than last year.
2.2 Solvency
IDP has an Altman-Z score of 3.24. This indicates that IDP is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.24, IDP is doing good in the industry, outperforming 78.67% of the companies in the same industry.
IDP has a debt to FCF ratio of 2.78. This is a good value and a sign of high solvency as IDP would need 2.78 years to pay back of all of its debts.
IDP has a Debt to FCF ratio of 2.78. This is amongst the best in the industry. IDP outperforms 81.33% of its industry peers.
A Debt/Equity ratio of 0.35 indicates that IDP is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.35, IDP perfoms like the industry average, outperforming 52.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.24 |
ROIC/WACC1.17
WACC8.29%
2.3 Liquidity
A Current Ratio of 2.72 indicates that IDP has no problem at all paying its short term obligations.
IDP has a Current ratio (2.72) which is in line with its industry peers.
IDP has a Quick Ratio of 2.04. This indicates that IDP is financially healthy and has no problem in meeting its short term obligations.
IDP has a Quick ratio of 2.04. This is comparable to the rest of the industry: IDP outperforms 53.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
3. Growth
3.1 Past
IDP shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.51%.
The earnings per share for IDP have been decreasing by -13.31% on average. This is quite bad
IDP shows a small growth in Revenue. In the last year, the Revenue has grown by 4.77%.
The Revenue has been decreasing by -7.62% on average over the past years.
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
3.2 Future
The Earnings Per Share is expected to grow by 0.52% on average over the next years.
Based on estimates for the next years, IDP will show a decrease in Revenue. The Revenue will decrease by -0.65% on average per year.
EPS Next Y-5.79%
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
EPS Next 5Y0.52%
Revenue Next Year1.35%
Revenue Next 2Y-1.88%
Revenue Next 3Y-1.34%
Revenue Next 5Y-0.65%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 10.03, the valuation of IDP can be described as reasonable.
IDP's Price/Earnings ratio is rather cheap when compared to the industry. IDP is cheaper than 92.00% of the companies in the same industry.
IDP's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.56.
With a Price/Forward Earnings ratio of 10.75, the valuation of IDP can be described as very reasonable.
IDP's Price/Forward Earnings ratio is rather cheap when compared to the industry. IDP is cheaper than 96.00% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of IDP to the average of the S&P500 Index (34.62), we can say IDP is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.03 | ||
| Fwd PE | 10.75 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IDP indicates a rather cheap valuation: IDP is cheaper than 89.33% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of IDP indicates a rather cheap valuation: IDP is cheaper than 92.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.87 | ||
| EV/EBITDA | 7.41 |
4.3 Compensation for Growth
IDP has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
5. Dividend
5.1 Amount
No dividends for IDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:IDP (11/17/2025, 7:00:00 PM)
144.1
+1.15 (+0.8%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners92.49%
Inst Owner ChangeN/A
Ins Owners0.14%
Ins Owner ChangeN/A
Market Cap21.13B
Revenue(TTM)10.07B
Net Income(TTM)1.61B
Analysts73.81
Price Target149.69 (3.88%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.2%
Min EPS beat(2)21.48%
Max EPS beat(2)38.92%
EPS beat(4)4
Avg EPS beat(4)19.59%
Min EPS beat(4)0.67%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)14.8%
EPS beat(12)12
Avg EPS beat(12)12.19%
EPS beat(16)14
Avg EPS beat(16)11.4%
Revenue beat(2)2
Avg Revenue beat(2)8.93%
Min Revenue beat(2)6.23%
Max Revenue beat(2)11.62%
Revenue beat(4)4
Avg Revenue beat(4)6.16%
Min Revenue beat(4)0.11%
Max Revenue beat(4)11.62%
Revenue beat(8)5
Avg Revenue beat(8)2.19%
Revenue beat(12)9
Avg Revenue beat(12)2.33%
Revenue beat(16)11
Avg Revenue beat(16)2%
PT rev (1m)1.04%
PT rev (3m)0.55%
EPS NQ rev (1m)-54.08%
EPS NQ rev (3m)-54.76%
EPS NY rev (1m)-4.15%
EPS NY rev (3m)1.63%
Revenue NQ rev (1m)-2.3%
Revenue NQ rev (3m)-2.13%
Revenue NY rev (1m)0.95%
Revenue NY rev (3m)5.45%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.03 | ||
| Fwd PE | 10.75 | ||
| P/S | 2.44 | ||
| P/FCF | 10.87 | ||
| P/OCF | 10.03 | ||
| P/B | 1.35 | ||
| P/tB | 10.32 | ||
| EV/EBITDA | 7.41 |
EPS(TTM)14.37
EY9.97%
EPS(NY)13.4
Fwd EY9.3%
FCF(TTM)13.25
FCFY9.2%
OCF(TTM)14.37
OCFY9.97%
SpS58.94
BVpS106.62
TBVpS13.97
PEG (NY)N/A
PEG (5Y)N/A
Graham Number185.67
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROCE | 11.07% | ||
| ROIC | 9.7% | ||
| ROICexc | 11.44% | ||
| ROICexgc | 40.96% | ||
| OM | 28.5% | ||
| PM (TTM) | 15.99% | ||
| GM | 75.24% | ||
| FCFM | 22.48% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.4%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexgc growth 3Y14.16%
ROICexgc growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.98%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Debt/EBITDA | 1.73 | ||
| Cap/Depr | 25% | ||
| Cap/Sales | 1.9% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 67.56% | ||
| Profit Quality | 140.56% | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 | ||
| Altman-Z | 3.24 |
F-Score5
WACC8.29%
ROIC/WACC1.17
Cap/Depr(3y)54.41%
Cap/Depr(5y)68.88%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.36%
Profit Quality(5y)121%
High Growth Momentum
Growth
EPS 1Y (TTM)2.51%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%17.89%
EPS Next Y-5.79%
EPS Next 2Y-2.63%
EPS Next 3Y-0.37%
EPS Next 5Y0.52%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%2.79%
Revenue Next Year1.35%
Revenue Next 2Y-1.88%
Revenue Next 3Y-1.34%
Revenue Next 5Y-0.65%
EBIT growth 1Y15.15%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year7.73%
EBIT Next 3Y2.84%
EBIT Next 5Y1.64%
FCF growth 1Y120.54%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y80.48%
OCF growth 3Y-7.55%
OCF growth 5Y-16.48%
BIOGEN INC / IDP.DE FAQ
What is the ChartMill fundamental rating of BIOGEN INC (IDP.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to IDP.DE.
Can you provide the valuation status for BIOGEN INC?
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.
What is the profitability of IDP stock?
BIOGEN INC (IDP.DE) has a profitability rating of 6 / 10.
Can you provide the financial health for IDP stock?
The financial health rating of BIOGEN INC (IDP.DE) is 7 / 10.
Can you provide the expected EPS growth for IDP stock?
The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to decline by -5.79% in the next year.